Carvedilol tied to improved survival in cirrhosis patients: Study
UK: Carvedilol improves survival in patients with cirrhosis and portal hypertension, suggests a recent study in the journal Alimentary Pharmacology & Therapeutics.
The standard of care in patients with cirrhosis and portal hypertension is primary prophylaxis of variceal haemorrhage with non‐selective beta blockers (NSBB) or variceal band ligation (VBL). NSBB, carvedilol in particular, may offer survival benefit. Considering this, Hannah R. McDowell, Royal Infirmary of Edinburgh, Edinburgh, UK, and colleagues aimed to assess mortality in a cohort of patients previously randomized to either carvedilol or VBL.
For the purpose, the researchers retrospectively analysed 152 patients (77 received carvedilol and 75 received VBL) recruited to a multi‐centre randomised controlled trial between 7 April 2000 and 24 June 2006. The trial was designed to assess the efficacy of VBL versus carvedilol in preventing first variceal bleed. Electronic records were used to undertake long‐term follow‐up (up to 20 years).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.